Is DTC pharma advertising coming to an end?

A bill introduced in Congress fulfills a Trump administration goal of ending direct pharma ads to patients.

By Amy Baxter • June 18, 2025

FDA to speed reviews for drugs supporting ‘national interests’

A new pilot program announced by FDA Commissioner Dr. Martin Makary would award vouchers that could cut drug reviews to one or two months — but only for products that meet a special criteria.

By Jonathan Gardner • June 18, 2025

Explore the Trendline➔

Big Pharma Business Strategies

Large pharmas are consistently tasked with the goal of growth. But in recent years, the upward trajectory has been littered with new hurdles. 

By PharmaVoice staff

How a patient group tackled research diversity for one disease and triggered change for pharma

A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.

By Meagan Parrish • June 17, 2025

Locked in a federal stalemate, states take PBM reform into their own hands

Arkansas is leading the nation in banning PBMs from owning pharmacies, as other states advance new restrictions.

By Amy Baxter • June 16, 2025

Will pharma finally score a policy win for 340B?

The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.

By Kelly Bilodeau • June 16, 2025

A day in the life of GSK’s U.S. president

How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.

By Meagan Parrish • June 13, 2025

Can ‘reputational pull’ save biotech from pharma’s image problem?

A reputation is tough to build and easy to bruise. For drugmakers stuck in reputational limbo, embracing a clear direction and forward-thinking strategy can foster a rosier image.  

By Michael Gibney • June 12, 2025

Pharma’s wins and losses in the budget bill

Key pharma reforms are up in the air as Republicans battle over their mammoth legislation that includes significant healthcare spending cuts.  

By Amy Baxter • June 11, 2025

The former Wall Street analyst shaping Novartis’ big-picture strategy

Ronny Gal, chief strategy and growth officer at Novartis, is guiding the company into a new era shaped by science-minded M&A and a slimmed-down pivot.

By Michael Gibney • June 10, 2025

COVID vax restrictions may not hamper uptake — but the market is still under pressure

If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space. 

By Alexandra Pecci • June 10, 2025

The mindfulness of medicine development: How scientists are driving the next wave of medical innovations

For millions of patients, the development of a new treatment or vaccine can be life-changing.

June 9, 2025

The biggest obesity deals of 2025 so far

Three pharma giants are snapping up new assets to find stronger footing in the quickly shifting weight loss market.

By Amy Baxter • June 9, 2025

With ADCs on the rise, drugmakers embrace a new oncology pillar

A slow ascent for more than two decades has given way to a sharp rise in important ADC readouts, marking a milestone era for targeted treatments.

By Michael Gibney • June 6, 2025

FDA’s Elsa AI is here, and the industry has questions

The agency has provided few details about its AI pilot as it makes moves on its “aggressive timeline” for rollout.  

By Amy Baxter • June 5, 2025

Biotech CEO confidence hits rock bottom amid policy shifts

A new survey sheds light on the way early-stage company leaders are grappling with regulatory headwinds.

By Meagan Parrish • June 4, 2025

Sanofi to acquire Blueprint for up to $9.5B

The pharma giant is betting that Blueprint, whose research revolves around a certain kind of tyrosine kinase, will be a boost to its immunology business.

By Jacob Bell • June 3, 2025

How leading oncology drugmakers set the stage for future advances

Drugmakers like J&J and Astellas are looking beyond today’s cancer treatments for the windows of opportunity decades down the road.

By Michael Gibney • June 3, 2025

The MAHA agenda won’t include expanding GLP-1 coverage — for now

Despite axing a Biden-era proposal for government coverage of obesity drugs, health officials have signaled a potential path forward.

By Amy Baxter • June 2, 2025

AbbVie’s ADC win shows how pharma can break through in solid tumors

 An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.

By Meagan Parrish • May 30, 2025

AI expertise is pharma’s next big hiring need — here’s what companies should look for

The widespread hunt for candidates who are equally versed in tech and healthcare is making AI recruiting a challenge. 

By Alexandra Pecci • May 29, 2025

Lilly to buy pain drug developer SiteOne, challenging Vertex

The acquisition expands Lilly’s pain pipeline with a slate of drugs targeting ion channel proteins like NaV1.7 and NaV1.8.

By Jacob Bell • May 28, 2025

What’s next for Trump’s ‘most favored nation’ policy?

HHS set drug price targets last week for pharma manufacturers, while lawmakers proposed new reforms.

By Amy Baxter • May 27, 2025

Turning the page: Novo’s CEO transition reflects Big Pharma’s era of change

Turnover of the top execs at pharma giants like J&J, AbbVie and Merck in the last few years illustrates the seismic industry shifts that often accompany leadership changes.

By Michael Gibney • May 22, 2025

Lilly’s former small molecule head makes the leap to a rising biotech in obesity

Utpal Singh joined the peptide-focused biotech Zealand Pharma last month after it notched a massive obesity deal with Roche.

By Amy Baxter • May 21, 2025

Regeneron wins bid to buy 23andMe out of bankruptcy

The biotech, which has for years invested in genetics research, plans to acquire "substantially all" of testing firm 23andMe's assets for $256 million.

By Ned Pagliarulo • May 20, 2025